Soleno Therapeutics(SLNO) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was $91.7 million, representing a sequential growth of nearly 40% from $66 million in Q3 2025 [18] - Full year 2025 total net revenue reached $190.4 million, with a positive net income of $20.9 million, marking a significant turnaround from a net loss of $175.9 million in 2024 [24] - Cash from operating activities for Q4 was $48.7 million, and the company ended the year with over $506 million in cash equivalents and marketable securities [5][18] Business Line Data and Key Metrics Changes - VYKAT XR, the company's primary product, achieved 1,250 patient start forms since its launch, capturing approximately 12.5% of the U.S. addressable market for Prader-Willi syndrome (PWS) [7][12] - Active treatment numbers increased from 764 at the end of Q3 to 859 by the end of Q4, indicating successful adoption into clinical practice [12] - The cumulative launch-to-date discontinuation rate related to adverse events was approximately 12% as of the end of Q4, with an expected long-term discontinuation rate of 15%-20% [8][14] Market Data and Key Metrics Changes - The company is targeting approximately 9,500 individuals living with PWS in the UK and EU4, with a concentrated market driven by centers of excellence [10] - Coverage for VYKAT XR has expanded to over 180 million lives across various channels, including commercial, Medicaid, and Medicare [16] Company Strategy and Development Direction - The company plans to expand beyond PWS, with Glycogen Storage Disease Type I (GSD I) identified as a potential new indication for VYKAT XR [26] - The strategy includes deepening experience and adoption among key opinion leaders (KOLs) and broadening the prescriber base in community settings [15][67] - The company is also considering commercialization options in the EU, with a focus on building its own team and capabilities [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum for VYKAT XR, with strong leading indicators for growth [7] - The company anticipates a regulatory decision for DCCR in the EU by mid-2026, following the submission of responses to Day 120 questions [9][78] - Management highlighted the importance of real-world safety profiles and the positive feedback from caregivers and prescribers regarding VYKAT XR [8][14] Other Important Information - The company has a strong balance sheet, allowing for continued investment in commercialization and potential new indications [19] - Research and development expenses for Q4 were $9.6 million, significantly lower than the previous year, reflecting a strategic focus on commercialization [21][22] Q&A Session Summary Question: What is the expected cadence for the 1,000 patient start forms over the next 9-12 months? - Management indicated that the start forms will come in over the year rather than in a specific quarter [31][32] Question: What percentage of the market could be accessible for PWS in the U.S.? - Management suggested that a higher penetration than the typical 40%-50% could be expected due to the lack of existing treatments [37] Question: What are the refill rates and how might the average weight of new patients change over time? - Management reported high adherence rates and indicated that the average weight of new patients is expected to increase as more older patients are treated [41][42] Question: How does the company view exclusivity and patent prosecution for VYKAT XR? - Management confirmed ongoing efforts to extend exclusivity through additional patents, with some patents potentially extending into the late 2030s [71] Question: What are the expectations for the EU approval process? - Management expressed cautious optimism, noting that the nature of the key questions from the EMA focused on efficacy data [78]